Vascular endothelial growth factor inhibitor-induced hypertension: Basics for primary care providers

Cardiology Research and Practice

Volumn 1, Issue 1, 2011, Pages

  Escalante, Carmen P ^a   Zalpour, Ali ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE BESYLATE; ANGIOGENESIS INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CEDIRANIB; DASATINIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NIFEDIPINE; NILOTINIB; NITRIC OXIDE; PAZOPANIB; PROSTACYCLIN; SORAFENIB; SUNITINIB; TELATINIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGINA PECTORIS; ARTERIAL STIFFNESS; ARTERY THROMBOSIS; BREAST CANCER; CARDIOMYOPATHY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; DIASTOLIC DYSFUNCTION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FLUID RETENTION; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FAILURE; HOME MONITORING; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; KIDNEY CARCINOMA; LIVER CARCINOMA; LOW DRUG DOSE; LUNG EDEMA; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; REVIEW; SIDE EFFECT; SOLID TUMOR; SUDDEN DEATH; THORAX PAIN; TORSADE DES POINTES; TRANSIENT ISCHEMIC ATTACK; TUMOR GROWTH; TUMOR VASCULARIZATION; UNITED STATES; VASCULAR RESISTANCE; VEIN THROMBOSIS;

EID: 79959426381     PISSN: None     EISSN: 20900597     Source Type: Journal    
DOI: 10.4061/2011/816897     Document Type: Review

References (41)

1. Folkman J., Angiogenesis in cancer, vascular, rheumatoid and other disease Nature Medicine 1995 1 1 27 31
2. Fidler I. J., Ellis L. M., The implications of angiogenesis for the biology and therapy of cancer metastasis Cell 1994 79 2 185 188 (Pubitemid 24324908)
3. Folkman J., Tumor angiogenesis: therapeutic implications The New England Journal of Medicine 1971 285 21 1182 1186
4. M D. M., Baluk P., Significance of blood vessel leakiness in cancer Cancer Research 2002 62 18 5381 5385 (Pubitemid 35024617)
5. Hanahan D., Folkman J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 1996 86 3 353 364 (Pubitemid 26272076)
6. Bergers G., Benjamin L. E., Tumorigenesis and the angiogenic switch Nature Reviews Cancer 2003 3 6 401 410 (Pubitemid 37328844)
7. Longo R., Sarmiento R., Fanelli M., Capaccetti B., Gattuso D., Gasparini G., Anti-angiogenic therapy: rationale, challenges and clinical studies Angiogenesis 2002 5 4 237 256 (Pubitemid 36875123)
8. Rak J., Filmus J., Kerbel R. S., Reciprocal paracrine interactions between tumour cells and endothelial cells: the angiogenesis progression hypothesis European Journal of Cancer Part A 1996 32 14 2438 2450
9. Kakeji Y., Teicher B. A., Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents Investigational New Drugs 1997 15 1 39 48 (Pubitemid 27217750)
10. Bevacizumab (Avastin). Package Insert. Genentech, Inc., http://www.avastin.com/
11. Sofafenib (Nexavar),. Package Insert. Bayer Healthcare Pharmaceuticals Inc., http://www.nexavar.com/
12. Sunitinib (Sutent),. Package Insert. Pfizer Inc., http://www.sutent.com/
13. Nitolinib (Tasigna),. Package Insert. Novartis Pharmaceuticals Corporation, http://www.us.tasigna.com/
14. Pazopanib (Votrient),. Package Insert. GlaxoSmithKlien, http://www.votrient.com/
15. Dasitinib (Sprycel),. Package Insert. Bristol-Myers Squibb Company, http://www.sprycel.com/
16. Chen I. I. H., Prewitt R. L., Dowell R. F., Microvascular rarefaction in spontaneously hypertensive rat cremaster muscle American Journal of Physiology 1981 10 3 306 310 (Pubitemid 11060204)
17. Hutchins P. M., Lynch C. D., Cooney P. T., Curseen K. A., The microcirculation in experimental hypertension and aging Cardiovascular Research 1996 32 4 772 780 (Pubitemid 26332316)
18. Steeghs N., Gelderblom H., Roodt J. O., Christensen O., Rajagopalan P., Hovens M., Putter H., Rabelink T. J., De Koning E., Hypertension and rarefaction during treatment with telatinib, a Small molecule angiogenesis inhibitor Clinical Cancer Research 2008 14 11 3470 3476
19. Veronese M. L., Mosenkis A., Flaherty K. T., Gallagher M., Stevenson J. P., Townsend R. R., O'Dwyer P. J., Mechanisms of hypertension associated with BAY 43-9006 Journal of Clinical Oncology 2006 24 9 1363 1369 (Pubitemid 46621999)
20. Wheeler-Jones C., Abu-Ghazaleh R., Cospedal R., Houliston R. A., Martin J., Zachary I., Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A 2 in endothelial cells via p42/p44 mitogen-activated protein kinase FEBS Letters 1997 420 1 28 32 (Pubitemid 28037194)
21. Roden D. M., Drug-induced prolongation of the QT interval The New England Journal of Medicine 2004 350 10 1013 1022 (Pubitemid 38269278)
22. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events. V3.0, DCTD, NCI, NIH, DHHs. March 2003, http://ctep.cancer.gov/
23. Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L., Jones D. W., Materson B. J., Oparil S., Wright J. T., Roccella E. J., The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report Journal of the American Medical Association 2003 289 19 2560 2572 (Pubitemid 37430158)
24. Yang J. C., Haworth L., Sherry R. M., Hwu P., Schwartzentruber D. J., Topalian S. L., Steinberg S. M., Chen H. X., Rosenberg S. A., A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer The New England Journal of Medicine 2003 349 5 427 434 (Pubitemid 36910021)
25. Johnson D. H., Fehrenbacher L., Novotny W. F., Herbst R. S., Nemunaitis J. J., Jablons D. M., Langer C. J., DeVore R. F., Gaudreault J., Damico L. A., Holmgren E., Kabbinavar F., Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer Journal of Clinical Oncology 2004 22 11 2184 2191 (Pubitemid 41095154)
26. Pande A. U., Lombardo J. C., Fakih M., Bevacizumab induced hypertension: a manageable toxicity (abstract) Journal of Clinical Oncology 2006 24 13539
27. Zhu X., Wu S., Dahut W. L., Parikh C. R., Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis American Journal of Kidney Diseases 2007 49 2 186 193 (Pubitemid 46178407)
28. Raman A. K., Lombardo J. C., Chandrasekhar R., Bevacizumab related adverse events among various age groups of elderly patients with advanced colorectal cancer (abstract) Journal of Clinical Oncology 2007 25 145 146
29. Choi Y. M., Shord S., Cuellar S., Examining ethnic differences for bevacizumab-induced hypertension and proteinuria (abstract) Journal of Clinical Oncology 2007 25 21168
30. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., Chevreau C., Filipek M., Melichar B., Bajetta E., Gorbunova V., Bay J. O., Bodrogi I., Jagiello-Gruszfeld A., Moore N., Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial The Lancet 2007 370 9605 2103 2111 (Pubitemid 350296300)
31. Azizi M., Chedid A., Oudard S., Home blood-pressure monitoring in patients receiving sunitinib The New England Journal of Medicine 2008 358 1 95 97
32. Veronese M. L., Flahert K. T., Townsend R., Pharmacodynamic study of the rat kinase inhibitor BAY 43-9006: mechanism of hypertension Journal of Clinical Oncology 2004 22 supplement: 135 poster no. 2035
33. Kantarjian H. M., Giles F., Gattermann N., Bhalla K., Alimena G., Palandri F., Ossenkoppele G. J., Nicolini F. E., O'Brien S. G., Litzow M., Bhatia R., Cervantes F., Haque A., Shou Y., Resta D. J., Weitzman A., Hochhaus A., Le Coutre P., Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 2007 110 10 3540 3546 (Pubitemid 350159618)
34. Taylor S. K., Chia S., Dent S., Clemons M., Agulnik M., Grenci P., Wang L., Oza A. M., Ivy P., Pritchard K. I., Leighl N. B., A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess margaret hospital phase II Consortium The Oncologist 2010 15 8 810 818
35. Quints-Cardama A., Kantarjian H., O'Brien S., Borthakur G., Bruzzi J., Munden R., Cortes J., Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure Journal of Clinical Oncology 2007 25 25 3908 3914 (Pubitemid 47477268)
36. Hurwitz H. I., Fehrenbacher L., Hainsworth J. D., Heim W., Berlin J., Holmgren E., Hambleton J., Novotny W. F., Kabbinavar F., Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer Journal of Clinical Oncology 2005 23 15 3502 3508
37. Dincer M., Altundag K., Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension Annals of Pharmacotherapy 2006 40 12 2278 2279 (Pubitemid 44954457)
38. Langenberg M. H. G., Van Herpen C. M. L., De Bono J., Schellens J. H. M., Unger C., Hoekman K., Blum H. E., Fiedler W., Drevs J., Le Maulf F., Fielding A., Robertson J., Voest E. E., Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors Journal of Clinical Oncology 2009 27 36 6152 6159
39. Maitland M. L., Moshier K., Imperial J., Blood pressure as a biomarker for sorafenib, an inhibitor of the VEGF signaling pathway Journal of Clinical Oncology 2006 24: 87s, supplement; abstract 2035
40. Maitland M. L., Ratain M. J., Terminal ballistics of kinase inhibitors: there are no magic bullets Annals of Internal Medicine 2006 145 9 702 703 (Pubitemid 46768848)
41. Maitland M. L., Bakris G. L., Black H. R., Chen H. X., Durand J. B., Elliott W. J., Ivy S. P., Leier C. V., Lindenfeld J., Liu G., Remick S. C., Steingart R., Tang W. H. W., Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors Journal of the National Cancer Institute 2010 102 9 596 604